BAFF Polypeptide for Selective Plasma Cell Targeting in Multiple Sclerosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like multiple sclerosis, such as anti-CD20 therapy and atacicept, do not effectively target plasma cells and can lead to disease exacerbations, highlighting a need for improved methods to regulate B cells and reduce inflammation in autoimmune diseases.
Innovation Solution
A composition comprising a B-cell Activating Factor (BAFF) polypeptide, an agent that promotes the survival and migration of gut-derived commensal-reactive B cells to the central nervous system, or an agent that depletes B cells, or a gut commensal that increases IgA levels, to treat autoimmune diseases by enriching gut-derived commensal-reactive IgA+ plasmablasts and plasma cells in the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD20 therapy is used to deplete B cells, then B cell depletion is achieved, but plasma cells are not effectively targeted and disease exacerbations occur
Solution Approach 1:
Instead of depleting all B cells (including protective ones), the invention inverts the approach by selectively depleting only pathogenic plasma cells through anti-CD38 therapy, while preserving regulatory B cells that produce IgA and IL-10. This selective inversion resolves the contradiction by achieving reliable pathogen targeting without causing disease exacerbation.
Solution Approach 2:
The invention applies local quality by differentiating between various B cell subsets and targeting only the pathogenic plasma cells with anti-CD38 therapy. By distinguishing pathogenic from protective B cells and applying selective depletion, the therapy achieves reliable pathogen targeting while avoiding harm to regulatory B cells.
2Object-affected harmful factors
If B cells are depleted to reduce inflammation, then inflammatory responses are suppressed, but immunoregulatory functions are also lost
Solution Approach 1:
The invention inverts the conventional approach by not depleting regulatory B cells but instead enhancing their function. By using agents that promote the survival and migration of regulatory IgA+ plasma cells and by depleting only pathogenic cells, the therapy reduces inflammation while maintaining or enhancing immunoregulatory functions.
Solution Approach 2:
The invention applies local quality by selectively targeting pathogenic B cells while preserving and enhancing regulatory B cell functions. Through selective depletion and promotion of specific B cell subsets, the therapy achieves inflammation reduction without compromising immunoregulatory reliability.
3Ease of manufacture
If conventional therapies are used to treat autoimmune diseases, then treatment is provided, but plasma cells are not effectively targeted
Solution Approach 1:
The invention changes the targeting parameter from CD20 (conventional therapy) to CD38 (pathogenic plasma cells). By using anti-CD38 therapy and selective agents that target plasma cells based on their specific markers and functions, the invention achieves reliable plasma cell targeting while maintaining treatment availability.
Data Source
Figure 1a~1f
Figure 2A~2F
Figure 3a~3h
AI summary
The present disclosure provides methods of treating an autoimmune disease (e.g., multiple sclerosis) or reducing inflammation by administering at least a B-cell activating Factor (BAFF) polypeptide to a subject in need thereof. The effect of BAFF on plasmablast/plasma cells and their role in autoimmune diseases is also disclosed.